# Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

> **NCT00306202** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 63 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Dasatinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00306202
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-31
- **Primary completion:** 2011-05-31
- **Final completion:** 2019-05-22
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306202, "Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00306202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*